Furthermore, SAAR elicited several outcomes in the heart: (1) induced alterations consistent with an enhanced myocardial energy metabolism; (2) differentially modulated the mRNA expression of the cardioprotective hormones FGF21 and adiponectin; (3) counteracted the HFD-induced expression of genes involved in cellular stress responses; (4) increased HW/BW ratios and natriuretic peptide gene expression—markers of cardiac hypertrophy. This evidence concerns the gene ADIPOQ and cardiac hypertrophy.